The effect of pharmaceutical care on quality of life and severity of adverse events from chemotherapy in chemotherapy patients at PhraChomKlao Hospital, Phetchaburi
Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci) · 10.09.2026
DOI: 10.14456/ijps.2026.9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci), erschienen am 10.09.2026. Verfasst von Sawitree Ketaim.
Themen: Patientensicherheit, Onkologische Pflege
Abstract (Originalsprache)
Oncology pharmacists play a critical role in providing pharmaceutical care to assess, prevent, and mitigate adverse drug reactions (ADRs), thereby enhancing the safety and quality of life (QoL) of cancer patients.
Methods
This pre-experimental, one-group pretest-posttest study evaluated quality of life (QoL) and ADR severity among chemotherapy patients receiving pharmaceutical care at Phrachomklao Hospital, Phetchaburi Province. A total of 90 patients enrolled in the “Pharmaceutical Care Program for Chemotherapy Patients” between January 1 and October 31, 2024. QoL was assessed using the standard EQ-5D-5L questionnaire, which measures health utility scores and self-reported health status via the Visual Analogue Scale (VAS) before and after chemotherapy cycles and the Common Terminology Criteria for Adverse Events (CTCAE) version 5 to grade ADR severity.
Results
No significant differences in QoL were observed between pre- and post-chemotherapy regarding mobility, self-care, and usual activities. Post-chemotherapy, pain/discomfort increased, whereas anxiety/depression decreased. While utility values remained stable, VAS scores demonstrated a significant upward (p=0.009) trend (77.01+13.11, 79.70+13.87,79.78+12.89 and 81.04+16.41, respectively), with significant improvements from baseline to cycle 1–3, and cycle 3 scores were significantly higher than cycle 2 (p < 0.05). Common mild ADRs included alopecia (74.5%), fatigue (64.8%), and peripheral neuropathy (37.8%). Severe ADRs were limited to seven cases: myalgia (5) and nausea/vomiting (2).
Conclusion
Pharmaceutical care significantly enhances QoL and reduces ADR severity. Continuous pharmaceutical care is recommended throughout treatment to ensure sustainable safety and efficacy in oncological care.
Schlagwörter
Zitieren
APA
Ketaim, S. (2026). The effect of pharmaceutical care on quality of life and severity of adverse events from chemotherapy in chemotherapy patients at PhraChomKlao Hospital, Phetchaburi. Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci). https://doi.org/10.14456/ijps.2026.9
Vancouver
Ketaim S. The effect of pharmaceutical care on quality of life and severity of adverse events from chemotherapy in chemotherapy patients at PhraChomKlao Hospital, Phetchaburi. Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci). 2026. doi:10.14456/ijps.2026.9
BibTeX
@article{Ketaim2026,
author = {Ketaim, Sawitree},
title = {The effect of pharmaceutical care on quality of life and severity of adverse events from chemotherapy in chemotherapy patients at PhraChomKlao Hospital, Phetchaburi},
journal = {Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)},
year = {2026},
doi = {10.14456/ijps.2026.9}
}
EUVIMED